Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
June 25, 2025 7:05 AM EDTSanofi to advance Kymeras next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474
In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile
Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,
and may opt-in to 50/50 development and profit share of KT-485 in the U.S.
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) --... More
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
June 25, 2025 7:00 AM EDTFOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors.
This press release features multimedia. View the full release here:... More
